Singapore Antifungal Drugs Market Analysis Report 2022 to 2030

Singapore Antifungal Drugs Market Analysis

$ 3999

Singapore Antifungal Drugs Market is at around $0.019 Bn in 2023 and is projected to reach $0.026 Bn in 2030, exhibiting a CAGR of 4.4% during the forecast period. The market is expanding due to rising awareness and education, advancements in healthcare infrastructure, and an increase in the incidence of fungal infections. The market is dominated by key players like Pfizer Inc., Merck & Co., Novartis AG, Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.

ID: IN10SGPH004 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Aneri Parekh

Buy Now

Singapore Antifungal Drugs Market Executive Summary

Singapore Antifungal Drugs Market is at around $0.01 9Bn in 2023 and is projected to reach $0.026 Bn in 2030, exhibiting a CAGR of 4.4% during the forecast period.

Producing, supplying, and marketing drugs intended to treat fungal infections domestically is the focus of Singapore's Antifungal drugs market. This market serves Singaporean patients suffering from fungal-related ailments by providing a range of antifungal medicine types, such as topical creams, oral drugs, and intravenous therapies. The dynamics and growth of this market in Singapore are greatly influenced by variables like the frequency of fungal infections, improvements in medication research, regulatory regulations, and healthcare infrastructure.

The market for antifungal medications in Singapore is steadily expanding due to rising public awareness of fungal infections and how to treat them. To meet the growing demand, major firms are launching cutting-edge formulas and broadening their product lines. Government programs that facilitate access to healthcare and improvements in the medical infrastructure also support market growth.

In 2023, antifungal drug sales reached $15.8 Bn worldwide. The efficacy and stability of antifungal medications have increased markedly. Significant investment has also been made in the antifungal drug sector, which has been essential to the sector's steady growth trend. The market for pharmaceutical antifungals is enormous due to rising profitability, productivity, and industrial innovation.

After its 2018 acquisition of Amplyx Pharmaceuticals, Pfizer is becoming increasingly prevalent in Singapore's Antifungal market. Fosmanogepix, Pfizer's primary antifungal candidate, is now undergoing Phase 2 clinical studies as a result of this acquisition. Pfizer may collaborate with other Singaporean businesses or academic organizations to create and market antifungal medications.

Singapore antifungal drugs market

Market Dynamics

Market Growth Drivers:

Growing Prevalence of Fungal Infections: The demand for Antifungal medications is fueled by the growing number of elderly people, the prevalence of immunocompromised diseases (such as HIV/AIDS, cancer, and diabetes), and the extensive use of immunosuppressive treatments.

Improvements in Healthcare Infrastructure: The demand for Antifungal medications increases as a result of improvements in the diagnosis and treatment of fungal infections brought on by developments in medical technology and healthcare services.

Growing Education and Awareness: Healthcare organizations' educational efforts and activities increase awareness and fuel the market for antifungal medications.

Market Restraints:

Exorbitant Treatment Cost: Antifungal medications can be costly, particularly when it comes to more recent and effective formulations. Particularly in environments with limited resources, the high cost of therapy may prevent some patient populations from receiving it or put pressure on healthcare finances.

Antifungal Resistance: Similar to antibiotic resistance, antifungal resistance is a global issue that is becoming more and more problematic. The advent of resistant fungal strains may reduce the efficacy of currently available antifungal medications, hence requiring the creation of novel treatments. This obstacle may prevent the current antifungal medications from growing in the market.

Side Effects and Toxicity: Certain antifungal medications may have serious adverse effects or toxicity profiles that make them unsuitable for usage, especially in more susceptible patient populations, like the elderly or people with weakened immune systems. Adverse effect concerns could affect patient compliance and prescription patterns.

Healthcare Policies and Regulatory Landscape

The Health Sciences Authority (HSA) is the statutory board that is part of the Ministry of Health in Singapore. It is a multidisciplinary organization whose job it is to protect and enhance public health and safety by applying knowledge in medicine, pharmacy, and science. The drug's quality, safety, and efficacy will all be assessed as part of the technical review of the application by the HSA. The screening procedure may take up to 180 working days. The HSA adheres to strict quality, safety, and efficacy standards in compliance with international standards (ICH). This could lead to rigorous and time-consuming criteria for pre-clinical and clinical trials, particularly for novel drugs.

Competitive Landscape

Key Players:

Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Abbott Laboratories
Astellas Pharma Inc.
GlaxoSmithKline plc
Bayer AG
Glenmark Pharmaceuticals Limited
Sanofi S.A.
Gilead Sciences Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Antifungal Drugs Market Segmentation

By Drug Class

Azoles
Echinocandins
Polyenes
Allylamines
Others

By Drug Indication

Dermatophytosis
Aspergillosis
Candidiasis
Others

By Drug Dosage

Oral drugs
Ointments
Powders
Others

By Infection

Systemic Antifungal Infections
Superficial Antifungal Infections

By Drug Distribution

Hospital Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.